A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

Abstract Background According to current evidence, the best treatment for fit patients with non-resectable pancreatic cancer (PC) is combination chemotherapy, whereas frail patients are recommended gemcitabine (Gem) monotherapy. Randomized controlled trials in colorectal cancer and a post-hoc analys...

Full description

Bibliographic Details
Main Authors: Louise Skau Rasmussen, Stine B. Winther, Inna M. Chen, Britta Weber, Lise Ventzel, Gabor Liposits, Julia Sidenius Johansen, Sönke Detlefsen, Ida Egendal, Susy Shim, Signe Christensen, Per Pfeiffer, Morten Ladekarl
Format: Article
Language:English
Published: BMC 2023-06-01
Series:BMC Cancer
Subjects:
Chemotherapy dose
Comorbidity
Frail
Older patients
Pancreatic cancer
Randomized study
Online Access:https://doi.org/10.1186/s12885-023-11035-6

Internet

https://doi.org/10.1186/s12885-023-11035-6

Similar Items